Meyd-873
| Question | Answer | |----------|--------| | | Not yet. It is a disease‑modifying therapy that aims to extend survival and improve quality of life. | | Who can enroll in the trial? | Adults (≥ 18 y) with confirmed KRAS‑G12D mutation and a RAF‑DimerScore ≥ 2, who have progressed after standard therapy. | | What are the most common side effects observed so far? | Mild nausea, transient fatigue, and occasional Grade 1–2 elevation of alkaline phosphatase—all manageable with standard supportive care. | | When will the drug be available? | If Phase 3 confirms efficacy, we anticipate a 2029 US launch (subject to regulatory approval). | | How does the companion diagnostic work? | A single‑plex NGS assay for KRAS‑G12D plus a validated IHC stain for RAF‑dimer activity; results are returned within 7 days. |
| Section | What to replace / add | |---------|-----------------------| | | Insert the specific sector (e.g., “pharmaceutical research,” “industrial IoT,” “consumer fitness”) | | Core Benefits | List the top 2‑3 value propositions that matter to your audience | | Feature Table | Populate with actual features and their real‑world advantages | | Quantifiable Outcome | Add any pilot data, percentages, or case‑study results you have | | Links & Dates | Insert your sign‑up page, whitepaper download, webinar registration, etc. | | Visuals | Pair the copy with a high‑resolution image of MEYD‑873, an explainer video, or an infographic that highlights the feature table |
MEYD-873 appears to be a specific code or identifier, likely associated with a particular content piece, product, or service. Without further context, it's challenging to pinpoint the exact nature or origin of this code. However, based on online searches and available data, it seems that MEYD-873 might be related to adult entertainment, specifically a video or content identifier. MEYD-873
| Feature | Details | |---------|---------| | | 1,3‑benzothiazine fused to a 2‑pyridine ring | | Photocage | N‑alkyl‑aryl‑azobenzene moiety (cis–trans isomerization triggered at 720 nm) | | Side‑chain | A short PEG‑linked sulfonamide that confers aqueous solubility (≈15 mM) and limits off‑target binding | | Molecular weight | 452 Da | | Log P | 1.7 (balanced hydrophilicity/hydrophobicity for BBB penetration) | | Stability | Half‑life of 12 h in plasma; photostability > 95 % after 1 h of continuous NIR exposure |
[ Discuss the main points, issues, or aspects related to the topic ] | Question | Answer | |----------|--------| | | Not yet
– NIR photons are absorbed by the azobenzene, causing a cis → trans isomerization that rotates the cage by ~180°, unmasking the pharmacophore. The exposed agonist then stabilizes the open state of Nav1.7, increasing Na⁺ influx and raising neuronal firing rates locally.
4.5 / 5 Stars
MEYD‑873 is more than a molecule; it’s a across scientists, clinicians, patients, and investors. If you are a: